Comparative Pharmacology
Head-to-head clinical analysis: ENDOMETRIN versus NORETHINDRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDOMETRIN versus NORETHINDRONE.
ENDOMETRIN vs NORETHINDRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone is a steroid hormone that binds to progesterone receptors in the endometrium, inducing secretory changes, decreasing uterine contractility, and supporting pregnancy maintenance.
Norethindrone is a synthetic progestin that binds to progesterone receptors, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and inducing secretory changes in the endometrium. It also has weak androgenic and estrogenic activity.
Vaginal tablet: 100 mg twice daily starting on day 15 of a 28-day cycle for 12 weeks.
5 mg orally once daily for 5 days starting on day 5 of menstrual cycle or 0.35 mg orally once daily for contraception.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing for endometrial support.
Terminal elimination half-life: 5-14 hours (mean 8-10 hours); clinical context: requires once-daily dosing for steady state after ~2 days (5 half-lives).
Primarily renal (50-60% as metabolites, <10% unchanged); fecal (20-30%) via biliary excretion.
Renal (30-50% as glucuronide conjugates, 5-10% unchanged), fecal (<10%)
Category C
Category D/X
Progestin
Progestin